These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21666860)

  • 1. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
    Johnson DS; Stiff C; Lazerwith SE; Kesten SR; Fay LK; Morris M; Beidler D; Liimatta MB; Smith SE; Dudley DT; Sadagopan N; Bhattachar SN; Kesten SJ; Nomanbhoy TK; Cravatt BF; Ahn K
    ACS Med Chem Lett; 2011 Feb; 2(2):91-96. PubMed ID: 21666860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.
    Ahn K; Smith SE; Liimatta MB; Beidler D; Sadagopan N; Dudley DT; Young T; Wren P; Zhang Y; Swaney S; Van Becelaere K; Blankman JL; Nomura DK; Bhattachar SN; Stiff C; Nomanbhoy TK; Weerapana E; Johnson DS; Cravatt BF
    J Pharmacol Exp Ther; 2011 Jul; 338(1):114-24. PubMed ID: 21505060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
    Ahn K; Johnson DS; Fitzgerald LR; Liimatta M; Arendse A; Stevenson T; Lund ET; Nugent RA; Nomanbhoy TK; Alexander JP; Cravatt BF
    Biochemistry; 2007 Nov; 46(45):13019-30. PubMed ID: 17949010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders.
    Ahn K; Johnson DS; Cravatt BF
    Expert Opin Drug Discov; 2009 Jul; 4(7):763-784. PubMed ID: 20544003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Schweitzer BA; Wilcox MV; McDonald J; Smith SE; Foltin S; Rumsey J; Yang YS; Walker MC; Kamtekar S; Beidler D; Thorarensen A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6545-53. PubMed ID: 21924613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH).
    Min X; Thibault ST; Porter AC; Gustin DJ; Carlson TJ; Xu H; Lindstrom M; Xu G; Uyeda C; Ma Z; Li Y; Kayser F; Walker NP; Wang Z
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7379-84. PubMed ID: 21502526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis and in vivo evaluation of [18F]PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH).
    Skaddan MB; Zhang L; Johnson DS; Zhu A; Zasadny KR; Coelho RV; Kuszpit K; Currier G; Fan KH; Beck EM; Chen L; Drozda SE; Balan G; Niphakis M; Cravatt BF; Ahn K; Bocan T; Villalobos A
    Nucl Med Biol; 2012 Oct; 39(7):1058-67. PubMed ID: 22571907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.
    Ahn K; Johnson DS; Mileni M; Beidler D; Long JZ; McKinney MK; Weerapana E; Sadagopan N; Liimatta M; Smith SE; Lazerwith S; Stiff C; Kamtekar S; Bhattacharya K; Zhang Y; Swaney S; Van Becelaere K; Stevens RC; Cravatt BF
    Chem Biol; 2009 Apr; 16(4):411-20. PubMed ID: 19389627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided inhibitor design for human FAAH by interspecies active site conversion.
    Mileni M; Johnson DS; Wang Z; Everdeen DS; Liimatta M; Pabst B; Bhattacharya K; Nugent RA; Kamtekar S; Cravatt BF; Ahn K; Stevens RC
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12820-4. PubMed ID: 18753625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM-833 [(R)-N-(pyridazin-3-yl)-4-(7-(trifluoromethyl)chroman-4-yl)piperazine-1-carboxamide] in rats: Potential for the treatment of inflammatory pain.
    Endo T; Takeuchi T; Maehara S
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00569. PubMed ID: 32101384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperidine and piperazine inhibitors of fatty acid amide hydrolase targeting excitotoxic pathology.
    Lamani M; Malamas MS; Farah SI; Shukla VG; Almeida MF; Weerts CM; Anderson J; Wood JT; Farizatto KLG; Bahr BA; Makriyannis A
    Bioorg Med Chem; 2019 Dec; 27(23):115096. PubMed ID: 31629610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
    Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
    Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase.
    Scott CW; Tian G; Yu XH; Paschetto KA; Wilkins DE; Meury L; Cao CQ; Varnes J; Edwards PD
    Eur J Pharmacol; 2011 Sep; 667(1-3):74-9. PubMed ID: 21645511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
    Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
    Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor.
    Watabiki T; Tsuji N; Kiso T; Ozawa T; Narazaki F; Kakimoto S
    Eur J Pharmacol; 2017 Nov; 815():42-48. PubMed ID: 29017758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
    Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
    Mol Pain; 2016; 12():. PubMed ID: 27178246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
    Alexander JP; Cravatt BF
    J Am Chem Soc; 2006 Aug; 128(30):9699-704. PubMed ID: 16866524
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.